ABSTRACT

Serpiginous choroiditis (SC) is a rare, chronic, recurrent, progressive disease of unknown origin. The inflammatory process of SC can disrupt Bruch’s membrane, allowing occasional choroidal vascular growth, leading to significant visual loss even in the healed stages of the disease. Optical coherence tomography angiography (OCTA) can help in the detection of choroidal neovascular membrane (CNV), leading to a definitive diagnosis and thereby guide the initiation of intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment. We report herein two cases of SC complicated with a CNV detected with OCTA and treated with a series of anti-VEGF injections.

Introduction

Serpiginous choroiditis (SC), is a rare clinical entity characterized by irreversible damage primarily to the choriocapillaries and secondarily to the retinal pigment epithelium, the rest of the choroid, and the outer retina.^1,2 Lesions typically appear in the peripapillary area, but may extend to the macula as well.² The most common complication of SC is the development of choroidal neovascular membrane (CNV), which occurs in 10-35% of all cases.^3,4

Optical coherence tomography angiography (OCTA) is a novel non-invasive imaging modality that detects flow changes in the choroid, enabling stratified vascular analyses. Compared to fluorescein angiography (FA), OCTA provides high-resolution digital images of the different vascular layers, including the choriocapillaries and choroidal vessels. As a result, OCTA contributes significantly to the identification and monitoring of chorioretinopathies and their related complications such as CNV.^5,6,7,8,9,10

Within this context, we would like to present two cases of SC complicated with CNV, confirmed with OCTA, and treated with ranibizumab (Lucentis, Novartis, Greece).

Case Reports

Discussion

SC, first described by Hutchinson³ in 1900, is a rare, vision-threatening disease with a prevalence of between 0.2% and 5% of all uveitis cases. It affects individuals from 30 to 70 years old and presents with painless, blurred vision, metamorphopsias, and paracentral scotomas.^4,11 Initially it is unilateral, with the majority of cases demonstrating fellow eye involvement within 5 years. Confirmed unilateral cases are most commonly reported from tuberculosis-endemic countries.¹¹ Dilated fundus examination reveals asymmetric bilateral grayish-yellow lesions and mild inflammation of the vitreous body.⁴ Recurrences, usually symptomatic, occur at the edges of the scars.¹¹ Interestingly, the interval between recurrences varies from weeks to years.⁴ When no macular scarring exists, significant improvement of visual acuity is expected, similar to patient 1 and OD of patient 2 in our report. When CNV progresses to macular scarring, the visual outcome is less fortunate (patient 2, OS). The literature suggests that inflammation is the primary cause of CNV following age-related macular degeneration and myopia. Both infectious and non-infectious pathomechanisms can lead to the development of CNV. Although the overall incidence of CNV in non-infectious uveitides is only 2%, its prevalence is significantly higher in multifocal choroiditis, punctate inner choroiditis, and SC, which present with choroidal neovascularization in 32-46%, 17-40%, and 10-25% of all cases, respectively.^12,13 Especially in SC, CNV constitutes the most common complication. It typically originates from the border of the choroidal lesions inducing ischemia in the outer retina and inner choroidal layers.¹⁴ Taking into account that SC affects patients at their productive age, prompt diagnosis and treatment of SC-related CNV is of paramount importance to preserve visual capacity.⁷

It is known that among the prevalent theories regarding the pathogenesis of CNV is inflammatory-induced angiogenesis mediated by vascular endothelial growth factor (VEGF).^6,12,15 It is no surprise then, that the anti-VEGF medications exert a beneficial impact on CNV. Furthermore, damage to the RPE and Bruch’s membrane complex caused by chronic inflammation enables these new capillaries to pass from the choroid to the sub-RPE and subretinal space.^7,12,13 It should be mentioned that in patient 2, CNV in OD manifested prior to the characteristic clinical lesions of SC. To our knowledge, this is the first report of this peculiar incidence.

Contemporary imaging technologies contribute significantly to the diagnosis of SC and its related manifestations. OCTA is a non-invasive imaging modality that facilitates the diagnosis and management of retinal and choroidal diseases.^3,18 Recently, El Ameen and Herbort⁹ reported a case of SC diagnosed by OCTA and concluded that OCTA could even substitute for indocyanine green angiography.

OCTA seems to be useful in the diagnosis of SC-related complications as well, since its associated lesions present diagnostic difficulties with FA.⁷ OCTA has excellent reproducibility, is non-invasive, and is easily performed in few minutes.¹⁴ Although the use of OCTA in the diagnosis of type 1 CNV in age-related macular degeneration has been widely studied, published reports referring to the detection of the same complication in uveitis are limited.⁷

Campos Polo et al.⁶ used OCTA for the detection of CNV and its response to anti-VEGF injections in SC. Aggarwal et al.¹⁰ reported that OCTA is a helpful diagnostic tool for the detection of type 1 CNV in patients with tuberculous serpiginious-like choroiditis TB-SLC when conventional multimodal imaging methods fail to assist in the diagnosis. Astroz et al.¹⁶ indicated the diagnostic superiority of OCTA over FA in the detection of inflammatory CNV. Furthermore, Karti and Saatci¹³ reported that OCTA is useful not only in the differentiation of CNV from active inflammatory lesions, but it is also able to picture the characteristic lesions of white dot syndromes.

Until recently, the treatment options for SC-related CNV were photocoagulation, photodynamic therapy, and surgical excision.¹⁵ However, today intravitreal anti-VEGF injections are considered to be the first line of treatment.⁷ In our reported cases, we used ranibizumab, which contributed to BCVA improvement and regression of the inflammatory CNV. Our outcomes suggest that this therapeutic intervention is promising. Further cohorts of patients with SC are needed in order to draw safer conclusions in this direction.

Case 1

A 60-year-old woman was referred to the outpatient service of our department due to reduced visual acuity in her left eye. Her systemic history included systemic hypertension, dyslipidemia, and type 2 diabetes mellitus. A full ophthalmological examination was performed. Her best-corrected visual acuity (BCVA) was 20/25 and 20/40 in her right (OD) and left eye (OS), respectively. On dilated fundoscopy, no signs of diabetic retinopathy could be observed; however, the presence of peripapillary scarring in both eyes was detected (Figure 1A, B). OCT demonstrated macular pseudohole in OD and stage 2 macular hole in OS (Figure 2A, B). FA was performed and the diagnosis of SC was established (Figure 3A, B). The patient underwent a full systematic check-up, including Quantiferon Tb Gold test, which resulted negative. As there were no signs of active inflammation, no treatment was suggested at that time. Twenty-three months after initial presentation, the patient urgently visited our department due to bilateral blurred vision. Her BCVA had decreased to 20/50 and 20/200 in OD and OS, respectively. In OD a small subretinal hemorrhage with edema at the edge of the scar adjacent to the macula could be visualized. OCT showed the presence of hyperreflective lesion with intraretinal fluid (IRF) in the macular area of OD, while the macular hole in OS progressed to stage 4 (Figure 4A, B). OCTA revealed a CNV in the area corresponding to the hyperreflective lesion detected by OCT in the OD. To address the worsening clinical picture in OD, the patient was administered intravitreal ranibizumab. After three injections at 2-month intervals, BCVA improved to 20/25 with OCTA showing complete regression of the neovascular membrane (Figure 5). During the follow-up period of 16 months, the patient’s BCVA remained stable and no further intravitreal injection was required.

Case 2

A 55-year-old woman first presented to our outpatient service in March 2010 due to blurred vision in OS. Her systemic and ophthalmic history was uneventful. On presentation, BCVA was 20/20 in OD and counting fingers with positive Amsler test in OS. Dilated fundus examination revealed retinal edema and hemorrhage within the macular region in OS, while OD was normal (Figure 6). OCT detected the presence of subretinal fluid (SRF) under the fovea in OS (Figure 7). Subsequently, FA was performed and a neovascular membrane into the macular area was detected (Figure 8). Since there were no signs of any underlying disease at that time, the CNV was characterized as idiopathic and the patient was treated with 5 injections of intravitreal ranibizumab during the time period of 10 months. Her BCVA improved to 20/200 in OS, while the OCT showed complete regression of the SRF (Figure 9). In July 2012, her follow-up examination revealed the presence of peripapillary chorioretinal atrophy in OD (Figure 10A) and chorioretinal atrophy extending from the optic disc to the macula and the periphery in OS (Figure 10B), therefore the patient was diagnosed with SC. She underwent a full systemic check-up, including Quantiferon Tb Gold test, which resulted negative, and a regular follow-up program was suggested. Oral methotrexate (10 mg per week) was attempted; however, it was discontinued due to elevation of liver enzymes. As an alternative, short courses of oral methylprednisolone (Medrol, Pfizer, Greece) 16 mg per day was administered. Methylprednisolone contributed to the improvement of the SC-related retinal clinical picture of her OS which remained steady for a follow-up period of 6 years.

In June 2018, the patient visited our outpatient service again due to blurred vision in OD. Dilated fundoscopy and OCT imaging indicated no change in OS, however, BCVA in OD dropped to 20/50 with IRF and SRF (Figure 11). Due to deterioration of the clinical picture in OD, a course of oral methylprednisolone (32 mg per day) was administered, but there was no favorable response in BCVA or the clinical picture. Further increase in methylprednisolone was ruled out due to the patient’s development of Cushing-like systemic symptomatology. OCTA demonstrated a fine anastomotic network of vessels, suggestive of type 2 CNV secondary to SC. We concluded that the deterioration of the clinical picture was due to the CNV that was misdiagnosed as recurrence of the disease. Subsequently, the patient received three intravitreal injections of ranibizumab. Her BCVA stabilized at 20/25 with complete regression of both macular edema and CNV (Figure12).